Drug resistance and toxicity constitute challenging hurdles for cancer therapy. The application of nanotechnology for anticancer drug delivery is expected to address these issues and bring new hope for cancer treatment. In this context, we established an original nanomicellar drug delivery system based on an amphiphilic dendrimer (AmDM), which could generate supramolecular micelles to effectively encapsulate the anticancer drug doxorubicin (DOX) with high drug-loading capacity (>40%), thanks to the unique dendritic structure creating large void space for drug accommodation. The resulting AmDM/DOX nanomicelles were able to enhance drug potency and combat doxorubicin resistance in breast cancer models by significantly enhancing cellular uptake while considerably decreasing efflux of the drug. In addition, the AmDM/DOX nanoparticles abolished significantly the toxicity related to the free drug. Collectively, our studies demonstrate that the drug delivery system based on nanomicelles formed with the self-assembling amphiphilic dendrimer constitutes a promising and effective drug carrier in cancer therapy.amphiphilic dendrimers | supramolecular nanomicelles | drug delivery | cancer treatment | nanodrugs A lthough considerable progress has been made in cancer therapy, the complete cure and eradication of cancer remains one of the greatest challenges at present. A well-known hurdle is the drug resistance induced by chemotherapeutics, causing high recurrence rate and therapeutic failure (1). Moreover, high systemic toxicity of traditional anticancer drugs is another reason for eventual poor clinical outcome. To address these problems, the application of nanotechnology for drug delivery is widely expected to bring new hope for cancer treatment (2-6). Nanoparticle-based drug delivery systems can repress many drawbacks of traditional chemotherapeutics, such as high systematic toxicity and low therapeutic efficacy caused often by poor drug bioavailability, frequently related to the stability, solubility, and nonspecificity of drugs (2-8). In addition, nanodrugs with tailored properties can overcome drug resistance by increasing the drug accessibility and drug sensitivity via high local drug concentration achieved at tumor lesion through enhanced permeation and retention (EPR) effect (9-11). As a result, there is an increasing interest to develop effective nanodrugs for cancer treatment, and some of such systems have already made their way to clinical trials (2, 12, 13).Among various nanotechnology-based drug delivery systems, such as liposomes, nanomicelles, and nanotubes (7,8,14), nanomicelles have gained particular interest in cancer therapy by virtue of their appealing advantages such as high drug loading for effective therapeutic potency and small size (<30 nm) for deep tumor penetration (15, 16). The most common nanomicelles are constructed with lipids and amphiphilic polymers (12, 13). However, lipid-based nanomicelles have the drawback of limited stability, whereas polymers are plagued with dispersed molecular weight...